Pfizer Inc. (PFE - Analyst Report) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin.
When will the promised Wyeth piepline of biologics save us? We are knownn to be worst nowat developing antybodies thann even Medimune. Will Somerss is not answer
↧